SCHEMBL829185

SCHEMBL829185

C[C@H](O)CNN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1485019 1.00
SCHEMBL3269492 1.00
Hydrochloric Acid SCHEMBL20797075 0.97
Hydrochloric Acid SCHEMBL23039107 0.97
SCHEMBL21843495 0.75
SCHEMBL11463796 0.75
SCHEMBL19263520 0.73
Diisopropanolamine SCHEMBL10618901 0.72
Diisopropanolamine SCHEMBL22774 0.72
SCHEMBL9869011 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4074708-A1 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION Immunic AG (DE) 2022-10-19 EP disclosed
EP-3679034-B1 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION IMMUNIC AG (DE) 2022-06-01 EP disclosed
US-11292788-B2 IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation IMMUNIC AG (DE) 2022-04-05 US disclosed
US-20210061796-A1 IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation IMMUNIC AG (DE) 2021-03-04 US disclosed
CN-111433202-A 1- (4- (isoxazol-5-yl) -1H-pyrazol-1-yl) -2-methylpropan-2-ol derivatives and related compounds as I L-17 and IFN-gamma inhibitors for the treatment of autoimmune diseases and chronic inflammation 埃慕尼克股份公司 2020-07-17 CN disclosed
EP-3679034-A1 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION Immunic AG (DE) 2020-07-15 EP disclosed
WO-2019048541-A1 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION IMMUNIC AG (DE) 2019-03-14 WO disclosed
CN-104447765-A Tricyclic compound and pharmaceutical compositions thereof and application thereof SHENZHEN BOLIJIAN PHARMACEUTICAL CO LTD 2015-03-25 CN disclosed
EP-2010516-B1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA NV (BE) 2014-07-02 EP disclosed
CN-101472911-B Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA NV 2014-07-02 CN disclosed
CN-101098866-A Heteroaromatic quinoline compounds and their use as pde10 inhibitors PFIZER (US) 2008-01-02 CN disclosed
WO-2007118903-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-25 WO disclosed
EP-1841757-A2 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Pfizer Products Incorporated (US) 2007-10-10 EP disclosed
US-20060154931-A1 Heteroaromatic quinoline compounds PFIZER INC 2006-07-13 US disclosed
WO-2006072828-A2 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PFIZER PRODUCTS INC. (US) 2006-07-13 WO disclosed
EP-0700905-B1 Tricyclic pyrazole derivatives HOFFMANN LA ROCHE (CH) 2001-10-31 EP disclosed
CN-1056607-C Tricyclic pyrazole derivatives HOFFMANN LA ROCHE (CH) 2000-09-20 CN disclosed
US-5561150-A 1-AMINOALKYL-1,4-DIHYDROINDENO(2,1-C)PYRAZOLES OR 1H-BENZ(G)INDAZOLES; SEROTONIN RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM, PSYCHOLOGICAL AND GASTROINTESTINAL DISORDERS HOFFMAN-LA ROCHE INC. (US) 1996-10-01 US disclosed
CN-1131666-A Tricyclic pyrazole derivatives HOFFMANN LA ROCHE (CH) 1996-09-25 CN disclosed
EP-0700905-A1 Tricyclic pyrazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1996-03-13 EP disclosed